Home

Science & Medicine

Boston Scientific Rebuilds

Wed, 04/22/2009 - 06:14 by Brian Orelli

Boston Scientific (NYSE: BSX) has lots of new competition and a currency headwind, so flat sales from continuing operations are understandable. It wasn't enough to get investors excited, but should be enough to get the company started on a rebuilding year.

Takeda wins FDA approval for Uloric

Sun, 02/15/2009 - 11:23 by Abhishek Garg

Washington, February 15: The Food and Drug Administration (FDA) has authorized the sale of Uloric, a drug for the treatment of gout. This is the first drug for the disease that has been approved by FDA in the past four decades.